2-amino-3-(3,4-difluorophenyl)-3-oxopropionic acid methyl ester hydrochloride | 263023-96-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-amino-3-(3,4-difluorophenyl)-3-oxopropionic acid methyl ester hydrochloride
• 英文别名: Methyl 2-amino-3-(3,4-difluorophenyl)-3-oxopropanoate;hydrochloride
• CAS: 263023-96-7
• 化学式: C₁₀H₉F₂NO₃*ClH
• 分子量: 265.644
• InChiKey: GEYNCJZWJOBRIQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.07
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  69.4
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-amino-3-(3,4-difluorophenyl)-3-oxopropionic acid methyl ester hydrochloride 、 三氯乙酰异氰酸酯 以 1,4-二氧六环 为溶剂， 生成 1-trichloroacetyl-5-(3,4-difluorophenyl)-2,3-dihydro-4-methoxycarbonyl-2(1H)-imidazolone
  参考文献：
  名称：

  Imidazolones and their use in treating benign prostatic hyperplasia and

  摘要：

  这项发明涉及对人类α1a受体选择性拮抗剂的咪唑酮。这项发明还涉及利用这些化合物降低眼内压、抑制胆固醇合成、放松下尿道组织、治疗良性前列腺增生、阳痿、心律失常、交感介导的疼痛、偏头痛，以及治疗任何需要拮抗α1a受体的疾病。该发明还提供一种含有上述定义化合物的治疗有效量和药学可接受载体的药物组合物。

  公开号：

  US06046331A1

文献信息

• IMIDAZOLONES AND THEIR USE IN TREATING BENIGN PROSTATIC HYPERPLASIA AND OTHER DISORDERS
  申请人：SYNAPTIC PHARMACEUTICAL CORPORATION

  公开号：EP1140906A1

  公开（公告）日：2001-10-10
• EP1140906A4
  申请人：——

  公开号：EP1140906A4

  公开（公告）日：2002-03-13
• US6046331A
  申请人：——

  公开号：US6046331A

  公开（公告）日：2000-04-04
• [EN] IMIDAZOLONES AND THEIR USE IN TREATING BENIGN PROSTATIC HYPERPLASIA AND OTHER DISORDERS<br/>[FR] IMIDAZOLONES ET LEUR UTILISATION DANS LE TRAITEMENT DE L'HYPERPLASIE PROSTATIQUE BENIGNE ET D'AUTRES TROUBLES
  申请人：SYNAPTIC PHARMA CORP

  公开号：WO2000035907A1

  公开（公告）日：2000-06-22

  This invention is directed to imidazolones which are selective antagonists for human α1a receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia, sympathetic mediated pain, migraine, and for the treatment of any disease where the antagonism of the α1a receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.
• Imidazolones and their use in treating benign prostatic hyperplasia and
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US06046331A1

  公开（公告）日：2000-04-04

  This invention is directed to imidazolones which are selective antagonists for human .alpha..sub.1a receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia, sympathetic mediated pain, migraine, and for the treatment of any disease where the antagonism of the .alpha..sub.1a receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

  这项发明涉及对人类α1a受体选择性拮抗剂的咪唑酮。这项发明还涉及利用这些化合物降低眼内压、抑制胆固醇合成、放松下尿道组织、治疗良性前列腺增生、阳痿、心律失常、交感介导的疼痛、偏头痛，以及治疗任何需要拮抗α1a受体的疾病。该发明还提供一种含有上述定义化合物的治疗有效量和药学可接受载体的药物组合物。